Assertio Therapeutics (ASRT) AI Stock Analysis

• Market Cap: $75.53M
• Dividend Yield: N/A
• Average Volume (3M): 295.13K
• Price to Earnings (P/E): 1.9
• Beta (1Y): 0.90
• Revenue Growth: 9.21%
• EPS Growth: 58.12%
• Country: US
• Employees: 58
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -1.86
• Shares Outstanding: 6,416,806
• 10 Day Avg. Volume: 250,113
• 30 Day Avg. Volume: 295,133
• PEG Ratio: -0.05
• Price to Book (P/B): 0.62
• Price to Sales (P/S): 0.49
• P/FCF Ratio: -2.06
• Enterprise Value/Market Cap: 1.44
• Enterprise Value/Revenue: 0.92
• Enterprise Value/Gross Profit: 1.31
• Enterprise Value/Ebitda: 6.68
• 1Y Price Target: $36.00
• Price Target Upside: 205.86% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -2.57
• Revenue Forecast (FY): $110.14M

• Rating: 54 Neutral
• Price Target: $12.00 ▲(1.95% Upside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is held back primarily by weak financial performance—declining revenue, ongoing losses, and a 2025 turn to negative operating/free cash flow. Offsetting this are a cheap valuation (very low P/E) and a moderately positive earnings outlook driven by Robodon and cost savings, while technical signals remain largely neutral.

Positive Factors

Rolvedon core asset with long IP

Rolvedon is now integrated on Assertio’s label and commercial platform with demonstrated ~32% underlying demand growth and IP through 2039. This creates a multi-year, high‑margin revenue runway that can materially shift company economics and reduce reliance on legacy tails if execution holds.

High, stable gross margins

Product-level economics show ~70% gross margins, providing durable margin cushion versus revenue volatility. Strong gross margins allow operating leverage: as sales scale (notably from Rolvedon), incremental revenue can flow to EBITDA and support reinvestment without needing large gross-margin improvements.

Scalable commercial platform

Assertio’s nationwide sales force, GPO/distributor relationships and patient hub form a ready-to-use commercialization engine. That reduces incremental SG&A required for new in‑market specialty oncology launches, enabling faster, lower‑cost rollouts and better ROI on in‑licensed assets over the coming years.

Negative Factors

Multi-year revenue decline & losses

Revenue has trended lower for several years and the company remains unprofitable, reducing scale and financial flexibility. Continued top-line erosion increases dependence on a single growth asset to restore profitability, raising execution risk over the medium term if market penetration or reimbursement underperform expectations.

Negative operating and free cash flow in 2025

Cash generation deteriorated materially in 2025 with OCF and free cash flow turning negative and a sizeable sequential cash draw. If working capital normalization or Rolvedon cash conversion lags, liquidity could constrain marketing, M&A, or create reliance on financing, increasing strategic vulnerability.

Generic erosion on legacy product (Indocin)

Indocin represents a meaningful revenue tail exposed to generic entrants. Anticipated additional generic competition in 2026 implies predictable erosion of a core cash flow source, forcing the company to replace lost sales via Rolvedon or new acquisitions, which raises execution and timing risk for medium‑term cash and earnings.

Assertio Therapeutics Business Overview & Revenue Model

Company Description

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

How the Company Makes Money

Assertio makes money primarily by selling its marketed prescription pharmaceutical products in the U.S. Revenue is generated when these products are purchased through pharmaceutical distribution channels (e.g., wholesalers) and dispensed to patients via pharmacies, with net sales typically reflecting deductions such as rebates, chargebacks, and other customary pricing adjustments (specific amounts: null). The company’s key revenue stream is product net sales from its branded portfolio (current product-level breakdown and most recent material products: null). In addition to direct product sales, Assertio may generate other revenue from arrangements such as licensing, royalties, or milestone payments related to its product rights or collaborations; however, specific, current, and material partnership terms or royalty sources are not available in the prompt and are therefore reported as null. The company’s earnings can also be influenced by factors common to specialty pharma—such as payer coverage and formulary placement, generic competition, and regulatory/compliance requirements—while its strategy emphasizes acquiring or in-licensing assets and efficiently commercializing them to drive net sales (quantitative contribution of these factors: null).

Assertio Therapeutics Financial Statement Overview

Summary

Multi-year revenue decline and continued net losses weigh heavily, and 2025 saw a concerning shift to negative operating and free cash flow. Offsetting factors include solid ~70% gross margins and a not-overly-levered balance sheet (debt-to-equity ~0.42), but declining equity and weak returns reduce flexibility.

Income Statement

Revenue has been shrinking for several years (down 13.6% in 2025 vs. 2024, after declines in 2023–2024), indicating weakening demand and/or portfolio pressure. Gross margins remain solid (~70% in 2025), but profitability is inconsistent: the company swung from strong profits in 2022 to very large losses in 2023, and remained unprofitable in 2024–2025. Overall, the business shows decent product-level economics but poor and volatile bottom-line performance.

Balance Sheet

Leverage looks manageable with debt below equity (debt-to-equity ~0.42 in 2025), and total debt has stayed relatively stable versus prior years. However, equity has trended down since 2022, and returns on shareholders’ capital are meaningfully negative in 2023–2025, reflecting ongoing losses. The balance sheet is not overly levered, but declining equity and weak returns reduce financial flexibility.

Cash Flow

Cash generation deteriorated sharply: operating cash flow flipped from positive in 2022–2024 to negative in 2025, and free cash flow also moved negative. The year-over-year drop in free cash flow is severe in 2025, signaling either earnings pressure translating into cash burn and/or adverse working-capital dynamics. While cash flow previously supported the business (notably in 2022–2024), the latest year shows elevated liquidity risk if negative cash flow persists.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	118.71M	124.96M	152.07M	156.23M	111.01M
Gross Profit	83.33M	85.73M	125.05M	137.49M	95.18M
EBITDA	-21.54M	5.15M	53.17M	90.17M	38.78M
Net Income	-29.50M	-21.58M	-331.94M	109.63M	-1.28M
Balance Sheet
Total Assets	266.97M	284.73M	286.42M	413.91M	326.55M
Cash, Cash Equivalents and Short-Term Investments	63.41M	100.05M	73.44M	64.94M	36.81M
Total Debt	39.12M	40.27M	39.68M	66.87M	75.87M
Total Liabilities	173.02M	163.65M	148.42M	188.19M	224.13M
Stockholders Equity	93.95M	121.08M	138.00M	225.72M	102.41M
Cash Flow
Free Cash Flow	-28.18M	26.41M	48.98M	78.32M	5.47M
Operating Cash Flow	-28.18M	26.41M	49.60M	78.60M	5.52M
Investing Cash Flow	-11.99M	-48.91M	3.10M	-42.67M	-18.52M
Financing Cash Flow	-189.00K	-350.00K	-44.20M	-7.79M	29.03M

Assertio Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.77
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASRT, the sentiment is Positive. The current price of 11.77 is below the 20-day moving average (MA) of 11.82, above the 50-day MA of 11.43, and above the 200-day MA of 11.39, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 50.94 is Neutral, neither overbought nor oversold. The STOCH value of 44.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ASRT.

Assertio Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASRT	54 Neutral	$75.53M	1.85	-26.99%	―	9.21%	58.12%
CPIX	52 Neutral	$45.77M	-20.99	-10.54%	―	12.21%	69.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TLPH	51 Neutral	$36.94M	-2.09	-125.75%	―	-90.04%	44.40%
SCYX	50 Neutral	$40.15M	-3.67	-19.05%	―	-65.77%	38.61%
RMTI	42 Neutral	$37.64M	―	-16.77%	―	-23.60%	-179.33%
COSM	40 Underperform	$13.10M	-1.59	-63.82%	―	―	―

Assertio Therapeutics Corporate Events

Assertio Therapeutics Announces 1-for-15 Reverse Stock Split

On December 19, 2025, Assertio Holdings, Inc. filed an amendment to its certificate of incorporation to implement a 1-for-15 reverse stock split of its common stock, which had been approved by shareholders at the annual meeting on May 7, 2025. The reverse split will take effect at 12:01 a.m. Eastern Time on December 26, 2025, with ASRT shares beginning to trade on a split-adjusted basis that day under the same Nasdaq ticker but with a new CUSIP, consolidating every 15 existing shares into one new share, paying cash in lieu of fractional shares based on the December 24, 2025 closing price, and proportionately adjusting the conversion rate on its 6.5% Convertible Senior Notes due 2027 as well as all equity incentive plan instruments, while leaving the par value per share unchanged.

The most recent analyst rating on (ASRT) stock is a Hold with a $0.79 price target. To see the full list of analyst forecasts on Assertio Therapeutics stock, see the ASRT Stock Forecast page.